Australian biotech firm CSL partners with Amazon Web Services to speed up drug research

On September 29, 2026, Australian biotechnology firm CSL announced a collaboration with Amazon Web Services (AWS) to integrate AI and cloud technology into its research and clinical development pipeline. The partnership will enable CSL's scientists to analyze complex data and identify drug targets earlier, accelerating research and shortening development timelines. CSL will also use AWS tools to reduce manual work in protocol drafting, data management, and submissions. The announcement follows recent US drug-pricing agreements and CSL's better-than-expected annual earnings. Shares remained stable at A$181.9.